Vasogen's VP025 reduces inflammation in preclinical model of diabetic retinopathy

By Lisa Kerner

Erie, Pa., May 2 - Vasogen Inc. said findings from its VP025 drug development program demonstrated a significant reduction of several pro-inflammatory cytokines in a preclinical model of diabetes and diabetic retinopathy, a complication of diabetes that results in the loss of vision.

The findings were presented at the Scientific Sessions of the Association for Research in Vision and Ophthalmology Annual Meeting in Florida, according to a company news release.

In a preclinical model designed to develop diabetes, VP025 was shown to have a significant effect on reducing the expression of several pro-inflammatory cytokines including IL-1, IL-6, and MCP-1, in the retina.

The intramuscular administration of VP025 resulted in the increased expression of both IL-10 and TGF-beta, two potent anti-inflammatory cytokines, the company said.

VP025 has been shown to down-regulate microglial cell (inflammatory cells in the central nervous system) activation in preclinical models of neuro-inflammatory disease.

Located in Mississauqa, Ont., Vasogen develops technologies targeting the chronic inflammation underlying cardiovascular and neurological disease.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.